Pfizer (NYSE:PFE) Stock Price Up 0.2% – Here’s Why

Pfizer Inc. (NYSE:PFE)’s stock price was up 0.2% on Thursday . The stock traded as high as $24.86 and last traded at $24.74. Approximately 16,263,159 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 39,158,284 shares. The stock had previously closed at $24.70.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Bank of America restated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. UBS Group dropped their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Truist Financial dropped their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

The company has a market cap of $137.79 billion, a PE ratio of 17.23, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock’s 50-day simple moving average is $25.98 and its 200 day simple moving average is $26.83.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 earnings per share. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On Pfizer

A number of institutional investors and hedge funds have recently modified their holdings of the company. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the fourth quarter valued at $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the 4th quarter worth about $26,000. Clarity Asset Management Inc. acquired a new stake in Pfizer in the 4th quarter valued at about $27,000. Gould Capital LLC increased its holdings in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer during the fourth quarter worth about $28,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.